Measuring windows of selection for anti-malarial drug treatments

Malaria Journal

Volumn 14, Issue 1, 2015, Pages

  Kay, Katherine ^a   Hastings, Ian M ^a  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

Artemisinin combination therapy; Drug resistance; Malaria; Modelling; Pharmacodynamic; Pharmacokinetic; Window of selection

Indexed keywords

ANTIMALARIAL AGENT; ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTESUNATE; ARTESUNATE PLUS MEFLOQUINE; BENFLUMETOL; DIHYDROARTEMISININ; DIHYDROARTEMISININ PLUS PIPERAQUINE; MEFLOQUINE; PIPERAQUINE; ARTEMISININ DERIVATIVE; DRUG COMBINATION; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE; QUINOLINE DERIVATIVE;

ACCURACY; ARTICLE; CLINICAL STUDY; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SENSITIVITY; FOLLOW UP; HUMAN; IC50; MAJOR CLINICAL STUDY; MALARIA; MONOTHERAPY; NONHUMAN; PHARMACODYNAMICS; PROBABILITY; PROBABILITY OF SURVIVING DIRECT TREATMENT; REINFECTION; TREATMENT DURATION; WINDOWS OF SELECTION; BIOLOGICAL MODEL; DRUG COMBINATION; DRUG EFFECTS; MALARIA, FALCIPARUM; PARASITOLOGY; PLASMODIUM FALCIPARUM;

ANTIMALARIALS; ARTEMISININS; DRUG COMBINATIONS; ETHANOLAMINES; FLUORENES; HUMANS; MALARIA, FALCIPARUM; MODELS, BIOLOGICAL; PLASMODIUM FALCIPARUM; QUINOLINES;

EID: 84938367042     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-015-0810-4     Document Type: Article

References (34)

1. WHO Guidelines for the treatment of malaria (second edition) (2010). World Health Organization, Geneva, http://whqlibdoc.who.int/publications/2010/9789241547925-eng.pdf
2. Sisowath C, Strömberg J, Mårtensson A, Msellem M, Obondo C, Björkman A et al (2005) In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). J Infect Dis 191:1014-1017
3. Sisowath C, Ferreira PE, Bustamante LY, Dahlström S, Mårtensson A, Björkman A et al (2007) The role of pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa. Trop Med Int Health 12:736-742
4. Hastings IM, Watkins WM, White NJ (2002) The evolution of drug-resistant malaria: the role of drug elimination half-life. Phil Trans R Soc Lond B 357:505-519
5. Hastings IM, Watkins WM (2006) Tolerance is the key to understanding antimalarial drug resistance. Trends Parasitol 22:71-77
6. Watkins WM, Mosobo M (1993) Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. Trans R Soc Trop Med Hyg 87:75-78
7. von Seidlein L, Greenwood BM (2003) Mass administrations of antimalarial drugs. Trends Parasitol 19:452-460
8. WHO (2015) Malaria: draft global technical strategy: post 2015. World Health Organization, Geneva. http://apps.who.int/gb/ebwha/pdf-files/WHA68/A68-28-en.pdf?ua=1
9. WHO (2011) Global plan for artemisinin resistance containment. World Health Organization, Geneva, pp 1-88
10. WHO (2013) Emergency response to artemisinin resistance in the greater Mekong subregion. Regional Framework for action 2013-2015. World Health Organization, Geneva, pp 1-32
11. WHO (2011) Consideration of mass drug administration for the containment of artemisinin-resistant malaria in the Greater Mekong subregion: report of a consensus meeting, 27-28 September 2010. World Health Organization, Geneva, pp 1-40
12. Schellenberg D, Menendez C, Kahigwa E, Aponte J, Vidal J, Tanner M et al (2001) Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet 357:1471-1477
13. Cissé B, Sokhna C, Boulanger D, Milet J, Bâ EH, Richardson K et al (2006) Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomised, placebo-controlled, double-blind trial. Lancet 367:659-667
14. Marks F, von Kalckreuth V, Kobbe R, Adjei S, Adjei O, Horstmann RD et al (2005) Parasitological rebound effect and emergence of pyrimethamine resistance in Plasmodium falciparum after single-dose sulfadoxine-pyrimethamine. J Infect Dis 192:1963-1965
15. Hastings I, Ward S (2005) Coartem (Artemether-Lumefantrine) in Africa: the beginning of the end? J Infect Dis 192:1303-1304
16. Hodel EM, Genton B, Zanolari B, Mercier T, Duong S, Beck HP et al (2010) Residual antimalarial concentrations before treatment in patients with malaria from Cambodia: indication of drug pressure. J Infect Dis 202:1088-1094
17. Hodel EM, Kabanywanyi AM, Malila A, Zanolari B, Mercier T, Beck HP et al (2009) Residual antimalarials in malaria patients from Tanzania - implications on drug efficacy assessment and spread of parasite resistance. PLoS One 4:e8184
18. Talisuna A, Langi P, Bakyaita N, Egwang T, Mutabingwa T, Watkins W et al (2002) Intensity of malaria transmission, antimalarial drug use and resistance in Uganda: what is the relationship between these three factors? Trans R Soc Trop Med Hyg 96:310-317
19. Stepniewska K, White NJ (2008) Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob Agents 52:1589-1596
20. Winter K, Hastings IM (2011) Development, evaluation, and application of an in silico model for antimalarial drug treatment and failure. Antimicrob Agents Chemother 55:3380-3392
21. Kay K, Hastings IM (2013) Improving pharmacokinetic-pharmacodynamic modeling to investigate anti-infective chemotherapy with application to the current generation of antimalarial drugs. PLoS Comput Biol 9:e1003151
22. Hodel EM, Kay K, Hayes D, Terlouw D, Hastings I (2014) Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling. Malar J 13:138
23. WHO (2003) Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. World Health Organization, Geneva, pp 1-67
24. Sama W, Owusu-Agyei S, Felger I, Vounatsou P, Smith T (2005) An immigration - death model to estimate the duration of malaria infection when detectability of the parasite is imperfect. Stat Med 24:3269-3288
25. Sagara I, Diallo A, Kone M, Coulibaly M, Diawara SI, Guindo O et al (2008) A randomized trial of artesunate-mefloquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali. Am J Trop Med Hyg 79:655-661
26. Stepniewska K, White NJ (2008) Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob Agents Chemother 52:1589-1596
27. Hodel EMS, Guidi M, Zanolari B, Mercier T, Duong S, Kabanywanyi AM et al (2013) Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients. Malar J 12:235. doi: 10.1186/1475-2875-12-235
28. WHO (2008) Medicines for malaria venture: methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations. World Health Organization, Geneva, pp 1-54. http://www.who.int/malaria/publications/atoz/9789241596305/en/
29. Anderson T, Standwell N, Ecker A, Fidock D (2011) How can we identify parasite genes that underlie antimalarial drug resistance? Pharmacogenomics 140:1455-1467
30. Mwangi JM, Ranford-Cartwright L (2013) Genetic and genomic approaches for the discovery of parasite genes involved in antimalarial drug resistance. Parasitology 140:1455-1467
31. Hastings I (2011) How artemisinin-containing combination therapies slow the spread of antimalarial drug resistance. Trends Parasitol 27:67-72
32. Wargo AR, Huijben S, de Roode JC, Shepherd J, Read AF (2007) Competitive release and facilitation of drug-resistant parasites after therapeutic chemotherapy in a rodent malaria model. Proc Natl Acad Sci USA 104:19914-19919
33. Harrington WE, Mutabingwa TK, Muehlenbachs A, Sorensen B, Bolla MC, Fried M et al (2009) Competitive facilitation of drug-resistant Plasmodium falciparum malaria parasites in pregnant women who receive preventive treatment. Proc Natl Acad Sci USA 106:9027-9032
34. WHO (2011) World malaria report. World Health Organization, Geneva, pp 1-278